Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach

Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. GBM cells are highly resistant to apoptosis induced by antitumor drugs and radiotherapy resulting in cancer progression. We assessed whether a systems medicine approach, analysing the ability of tumor cells to execut...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cell death & disease 2013-05, Vol.4 (5), p.e629-e629
Hauptverfasser: Murphy, Á C, Weyhenmeyer, B, Schmid, J, Kilbride, S M, Rehm, M, Huber, H J, Senft, C, Weissenberger, J, Seifert, V, Dunst, M, Mittelbronn, M, Kögel, D, Prehn, J H M, Murphy, B M
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e629
container_issue 5
container_start_page e629
container_title Cell death & disease
container_volume 4
creator Murphy, Á C
Weyhenmeyer, B
Schmid, J
Kilbride, S M
Rehm, M
Huber, H J
Senft, C
Weissenberger, J
Seifert, V
Dunst, M
Mittelbronn, M
Kögel, D
Prehn, J H M
Murphy, B M
description Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. GBM cells are highly resistant to apoptosis induced by antitumor drugs and radiotherapy resulting in cancer progression. We assessed whether a systems medicine approach, analysing the ability of tumor cells to execute apoptosis could be utilized to predict the response of GBM patients to treatment. Concentrations of the key proapoptotic proteins procaspase-3, procaspase-9, Smac and Apaf-1 and the antiapopotic protein XIAP were determined in a panel of GBM cell lines and GBM patient tumor resections. These values were used as input for APOPTO-CELL, a systems biological based mathematical model built to predict cellular susceptibility to undergo caspase activation. The modeling was capable of accurately distinguishing between GBM cells that die or survive in response to treatment with temozolomide in 10 of the 11 lines analysed. Importantly the results obtained using GBM patient samples show that APOPTO-CELL was capable of stratifying patients according to their progression-free survival times and predicted the ability of tumor cells to support caspase activation in 16 of the 21 GBM patients analysed. Calculating the susceptibility to apoptosis execution may be a potent tool in predicting GBM patient therapy responsiveness and may allow for the use of APOPTO-CELL in a clinical setting.
doi_str_mv 10.1038/cddis.2013.157
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3674364</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4042524271</sourcerecordid><originalsourceid>FETCH-LOGICAL-c491t-449ff5393a56785211801e599be9143d1cecb68c5efd097238962778fad7d47a3</originalsourceid><addsrcrecordid>eNptkU1v1DAQhi0EolXplSOyxIVLtnbs-IMDUlVBi1SJC5wtrzPZukri4ElW9M4Px2FLtSB8sa15_HhGLyGvOdtwJsxFaNuIm5pxseGNfkZOayZ5JY2xz4_OJ-Qc8Z6VJQSrG_WSnNRCGV7X8pT8vAxz3Ps5ppGmjsIPCMt6gUyDx8kjII1IPZ0ytDHMKa_YlNMuA2IBqy4DUFzyvmh6Gke662Pa9h7nNJRnRQ3jjO-LAh9whgHpsJriCNRPReTD3SvyovM9wvnjfka-ffr49eqmuv1y_fnq8rYK0vK5ktJ2XSOs8I3Spqk5N4xDY-0WLJei5QHCVpnQQNcyq2thrKq1Np1vdSu1F2fkw8E7LdvSRCiNZd-7KcfB5weXfHR_V8Z453Zp74TSUihZBO8eBTl9XwBnN0QM0Pd-hLSg49oyqzSTrKBv_0Hv05LHMl6hjCqkVLxQmwMVckLM0D01w5lbM3a_M3Zrxq5kXB68OR7hCf-TaAEuDgCW0riDfPTv_5W_AA1UtZQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1786179461</pqid></control><display><type>article</type><title>Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Springer Nature OA Free Journals</source><source>Nature Free</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Murphy, Á C ; Weyhenmeyer, B ; Schmid, J ; Kilbride, S M ; Rehm, M ; Huber, H J ; Senft, C ; Weissenberger, J ; Seifert, V ; Dunst, M ; Mittelbronn, M ; Kögel, D ; Prehn, J H M ; Murphy, B M</creator><creatorcontrib>Murphy, Á C ; Weyhenmeyer, B ; Schmid, J ; Kilbride, S M ; Rehm, M ; Huber, H J ; Senft, C ; Weissenberger, J ; Seifert, V ; Dunst, M ; Mittelbronn, M ; Kögel, D ; Prehn, J H M ; Murphy, B M</creatorcontrib><description>Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. GBM cells are highly resistant to apoptosis induced by antitumor drugs and radiotherapy resulting in cancer progression. We assessed whether a systems medicine approach, analysing the ability of tumor cells to execute apoptosis could be utilized to predict the response of GBM patients to treatment. Concentrations of the key proapoptotic proteins procaspase-3, procaspase-9, Smac and Apaf-1 and the antiapopotic protein XIAP were determined in a panel of GBM cell lines and GBM patient tumor resections. These values were used as input for APOPTO-CELL, a systems biological based mathematical model built to predict cellular susceptibility to undergo caspase activation. The modeling was capable of accurately distinguishing between GBM cells that die or survive in response to treatment with temozolomide in 10 of the 11 lines analysed. Importantly the results obtained using GBM patient samples show that APOPTO-CELL was capable of stratifying patients according to their progression-free survival times and predicted the ability of tumor cells to support caspase activation in 16 of the 21 GBM patients analysed. Calculating the susceptibility to apoptosis execution may be a potent tool in predicting GBM patient therapy responsiveness and may allow for the use of APOPTO-CELL in a clinical setting.</description><identifier>ISSN: 2041-4889</identifier><identifier>EISSN: 2041-4889</identifier><identifier>DOI: 10.1038/cddis.2013.157</identifier><identifier>PMID: 23681224</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/553 ; 631/67/1922 ; 631/80/82/23 ; 692/700/565 ; Adult ; Aged ; Algorithms ; Antibodies ; Antineoplastic Agents, Alkylating - toxicity ; Apoptotic Protease-Activating Factor 1 - metabolism ; Biochemistry ; Biomedical and Life Sciences ; Brain Neoplasms - metabolism ; Brain Neoplasms - pathology ; Caspase 3 - metabolism ; Caspase 9 - metabolism ; Caspases - metabolism ; Cell Biology ; Cell Culture ; Cell Survival - drug effects ; Dacarbazine - analogs &amp; derivatives ; Dacarbazine - toxicity ; Disease-Free Survival ; Female ; Glioblastoma - metabolism ; Glioblastoma - pathology ; Humans ; Immunology ; Intracellular Signaling Peptides and Proteins - metabolism ; Life Sciences ; Male ; Middle Aged ; Mitochondrial Proteins - metabolism ; Original ; original-article ; X-Linked Inhibitor of Apoptosis Protein - metabolism</subject><ispartof>Cell death &amp; disease, 2013-05, Vol.4 (5), p.e629-e629</ispartof><rights>The Author(s) 2013</rights><rights>Copyright Nature Publishing Group May 2013</rights><rights>Copyright © 2013 Macmillan Publishers Limited 2013 Macmillan Publishers Limited</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c491t-449ff5393a56785211801e599be9143d1cecb68c5efd097238962778fad7d47a3</citedby><cites>FETCH-LOGICAL-c491t-449ff5393a56785211801e599be9143d1cecb68c5efd097238962778fad7d47a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674364/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674364/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23681224$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Murphy, Á C</creatorcontrib><creatorcontrib>Weyhenmeyer, B</creatorcontrib><creatorcontrib>Schmid, J</creatorcontrib><creatorcontrib>Kilbride, S M</creatorcontrib><creatorcontrib>Rehm, M</creatorcontrib><creatorcontrib>Huber, H J</creatorcontrib><creatorcontrib>Senft, C</creatorcontrib><creatorcontrib>Weissenberger, J</creatorcontrib><creatorcontrib>Seifert, V</creatorcontrib><creatorcontrib>Dunst, M</creatorcontrib><creatorcontrib>Mittelbronn, M</creatorcontrib><creatorcontrib>Kögel, D</creatorcontrib><creatorcontrib>Prehn, J H M</creatorcontrib><creatorcontrib>Murphy, B M</creatorcontrib><title>Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach</title><title>Cell death &amp; disease</title><addtitle>Cell Death Dis</addtitle><addtitle>Cell Death Dis</addtitle><description>Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. GBM cells are highly resistant to apoptosis induced by antitumor drugs and radiotherapy resulting in cancer progression. We assessed whether a systems medicine approach, analysing the ability of tumor cells to execute apoptosis could be utilized to predict the response of GBM patients to treatment. Concentrations of the key proapoptotic proteins procaspase-3, procaspase-9, Smac and Apaf-1 and the antiapopotic protein XIAP were determined in a panel of GBM cell lines and GBM patient tumor resections. These values were used as input for APOPTO-CELL, a systems biological based mathematical model built to predict cellular susceptibility to undergo caspase activation. The modeling was capable of accurately distinguishing between GBM cells that die or survive in response to treatment with temozolomide in 10 of the 11 lines analysed. Importantly the results obtained using GBM patient samples show that APOPTO-CELL was capable of stratifying patients according to their progression-free survival times and predicted the ability of tumor cells to support caspase activation in 16 of the 21 GBM patients analysed. Calculating the susceptibility to apoptosis execution may be a potent tool in predicting GBM patient therapy responsiveness and may allow for the use of APOPTO-CELL in a clinical setting.</description><subject>631/553</subject><subject>631/67/1922</subject><subject>631/80/82/23</subject><subject>692/700/565</subject><subject>Adult</subject><subject>Aged</subject><subject>Algorithms</subject><subject>Antibodies</subject><subject>Antineoplastic Agents, Alkylating - toxicity</subject><subject>Apoptotic Protease-Activating Factor 1 - metabolism</subject><subject>Biochemistry</subject><subject>Biomedical and Life Sciences</subject><subject>Brain Neoplasms - metabolism</subject><subject>Brain Neoplasms - pathology</subject><subject>Caspase 3 - metabolism</subject><subject>Caspase 9 - metabolism</subject><subject>Caspases - metabolism</subject><subject>Cell Biology</subject><subject>Cell Culture</subject><subject>Cell Survival - drug effects</subject><subject>Dacarbazine - analogs &amp; derivatives</subject><subject>Dacarbazine - toxicity</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Glioblastoma - metabolism</subject><subject>Glioblastoma - pathology</subject><subject>Humans</subject><subject>Immunology</subject><subject>Intracellular Signaling Peptides and Proteins - metabolism</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Mitochondrial Proteins - metabolism</subject><subject>Original</subject><subject>original-article</subject><subject>X-Linked Inhibitor of Apoptosis Protein - metabolism</subject><issn>2041-4889</issn><issn>2041-4889</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNptkU1v1DAQhi0EolXplSOyxIVLtnbs-IMDUlVBi1SJC5wtrzPZukri4ElW9M4Px2FLtSB8sa15_HhGLyGvOdtwJsxFaNuIm5pxseGNfkZOayZ5JY2xz4_OJ-Qc8Z6VJQSrG_WSnNRCGV7X8pT8vAxz3Ps5ppGmjsIPCMt6gUyDx8kjII1IPZ0ytDHMKa_YlNMuA2IBqy4DUFzyvmh6Gke662Pa9h7nNJRnRQ3jjO-LAh9whgHpsJriCNRPReTD3SvyovM9wvnjfka-ffr49eqmuv1y_fnq8rYK0vK5ktJ2XSOs8I3Spqk5N4xDY-0WLJei5QHCVpnQQNcyq2thrKq1Np1vdSu1F2fkw8E7LdvSRCiNZd-7KcfB5weXfHR_V8Z453Zp74TSUihZBO8eBTl9XwBnN0QM0Pd-hLSg49oyqzSTrKBv_0Hv05LHMl6hjCqkVLxQmwMVckLM0D01w5lbM3a_M3Zrxq5kXB68OR7hCf-TaAEuDgCW0riDfPTv_5W_AA1UtZQ</recordid><startdate>20130501</startdate><enddate>20130501</enddate><creator>Murphy, Á C</creator><creator>Weyhenmeyer, B</creator><creator>Schmid, J</creator><creator>Kilbride, S M</creator><creator>Rehm, M</creator><creator>Huber, H J</creator><creator>Senft, C</creator><creator>Weissenberger, J</creator><creator>Seifert, V</creator><creator>Dunst, M</creator><creator>Mittelbronn, M</creator><creator>Kögel, D</creator><creator>Prehn, J H M</creator><creator>Murphy, B M</creator><general>Nature Publishing Group UK</general><general>Springer Nature B.V</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7TO</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20130501</creationdate><title>Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach</title><author>Murphy, Á C ; Weyhenmeyer, B ; Schmid, J ; Kilbride, S M ; Rehm, M ; Huber, H J ; Senft, C ; Weissenberger, J ; Seifert, V ; Dunst, M ; Mittelbronn, M ; Kögel, D ; Prehn, J H M ; Murphy, B M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c491t-449ff5393a56785211801e599be9143d1cecb68c5efd097238962778fad7d47a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>631/553</topic><topic>631/67/1922</topic><topic>631/80/82/23</topic><topic>692/700/565</topic><topic>Adult</topic><topic>Aged</topic><topic>Algorithms</topic><topic>Antibodies</topic><topic>Antineoplastic Agents, Alkylating - toxicity</topic><topic>Apoptotic Protease-Activating Factor 1 - metabolism</topic><topic>Biochemistry</topic><topic>Biomedical and Life Sciences</topic><topic>Brain Neoplasms - metabolism</topic><topic>Brain Neoplasms - pathology</topic><topic>Caspase 3 - metabolism</topic><topic>Caspase 9 - metabolism</topic><topic>Caspases - metabolism</topic><topic>Cell Biology</topic><topic>Cell Culture</topic><topic>Cell Survival - drug effects</topic><topic>Dacarbazine - analogs &amp; derivatives</topic><topic>Dacarbazine - toxicity</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Glioblastoma - metabolism</topic><topic>Glioblastoma - pathology</topic><topic>Humans</topic><topic>Immunology</topic><topic>Intracellular Signaling Peptides and Proteins - metabolism</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Mitochondrial Proteins - metabolism</topic><topic>Original</topic><topic>original-article</topic><topic>X-Linked Inhibitor of Apoptosis Protein - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Murphy, Á C</creatorcontrib><creatorcontrib>Weyhenmeyer, B</creatorcontrib><creatorcontrib>Schmid, J</creatorcontrib><creatorcontrib>Kilbride, S M</creatorcontrib><creatorcontrib>Rehm, M</creatorcontrib><creatorcontrib>Huber, H J</creatorcontrib><creatorcontrib>Senft, C</creatorcontrib><creatorcontrib>Weissenberger, J</creatorcontrib><creatorcontrib>Seifert, V</creatorcontrib><creatorcontrib>Dunst, M</creatorcontrib><creatorcontrib>Mittelbronn, M</creatorcontrib><creatorcontrib>Kögel, D</creatorcontrib><creatorcontrib>Prehn, J H M</creatorcontrib><creatorcontrib>Murphy, B M</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cell death &amp; disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Murphy, Á C</au><au>Weyhenmeyer, B</au><au>Schmid, J</au><au>Kilbride, S M</au><au>Rehm, M</au><au>Huber, H J</au><au>Senft, C</au><au>Weissenberger, J</au><au>Seifert, V</au><au>Dunst, M</au><au>Mittelbronn, M</au><au>Kögel, D</au><au>Prehn, J H M</au><au>Murphy, B M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach</atitle><jtitle>Cell death &amp; disease</jtitle><stitle>Cell Death Dis</stitle><addtitle>Cell Death Dis</addtitle><date>2013-05-01</date><risdate>2013</risdate><volume>4</volume><issue>5</issue><spage>e629</spage><epage>e629</epage><pages>e629-e629</pages><issn>2041-4889</issn><eissn>2041-4889</eissn><abstract>Glioblastoma (GBM) is the most common and aggressive primary brain tumor in adults. GBM cells are highly resistant to apoptosis induced by antitumor drugs and radiotherapy resulting in cancer progression. We assessed whether a systems medicine approach, analysing the ability of tumor cells to execute apoptosis could be utilized to predict the response of GBM patients to treatment. Concentrations of the key proapoptotic proteins procaspase-3, procaspase-9, Smac and Apaf-1 and the antiapopotic protein XIAP were determined in a panel of GBM cell lines and GBM patient tumor resections. These values were used as input for APOPTO-CELL, a systems biological based mathematical model built to predict cellular susceptibility to undergo caspase activation. The modeling was capable of accurately distinguishing between GBM cells that die or survive in response to treatment with temozolomide in 10 of the 11 lines analysed. Importantly the results obtained using GBM patient samples show that APOPTO-CELL was capable of stratifying patients according to their progression-free survival times and predicted the ability of tumor cells to support caspase activation in 16 of the 21 GBM patients analysed. Calculating the susceptibility to apoptosis execution may be a potent tool in predicting GBM patient therapy responsiveness and may allow for the use of APOPTO-CELL in a clinical setting.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>23681224</pmid><doi>10.1038/cddis.2013.157</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2041-4889
ispartof Cell death & disease, 2013-05, Vol.4 (5), p.e629-e629
issn 2041-4889
2041-4889
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3674364
source MEDLINE; DOAJ Directory of Open Access Journals; Springer Nature OA Free Journals; Nature Free; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects 631/553
631/67/1922
631/80/82/23
692/700/565
Adult
Aged
Algorithms
Antibodies
Antineoplastic Agents, Alkylating - toxicity
Apoptotic Protease-Activating Factor 1 - metabolism
Biochemistry
Biomedical and Life Sciences
Brain Neoplasms - metabolism
Brain Neoplasms - pathology
Caspase 3 - metabolism
Caspase 9 - metabolism
Caspases - metabolism
Cell Biology
Cell Culture
Cell Survival - drug effects
Dacarbazine - analogs & derivatives
Dacarbazine - toxicity
Disease-Free Survival
Female
Glioblastoma - metabolism
Glioblastoma - pathology
Humans
Immunology
Intracellular Signaling Peptides and Proteins - metabolism
Life Sciences
Male
Middle Aged
Mitochondrial Proteins - metabolism
Original
original-article
X-Linked Inhibitor of Apoptosis Protein - metabolism
title Activation of executioner caspases is a predictor of progression-free survival in glioblastoma patients: a systems medicine approach
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T01%3A58%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Activation%20of%20executioner%20caspases%20is%20a%20predictor%20of%20progression-free%20survival%20in%20glioblastoma%20patients:%20a%20systems%20medicine%20approach&rft.jtitle=Cell%20death%20&%20disease&rft.au=Murphy,%20%C3%81%20C&rft.date=2013-05-01&rft.volume=4&rft.issue=5&rft.spage=e629&rft.epage=e629&rft.pages=e629-e629&rft.issn=2041-4889&rft.eissn=2041-4889&rft_id=info:doi/10.1038/cddis.2013.157&rft_dat=%3Cproquest_pubme%3E4042524271%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1786179461&rft_id=info:pmid/23681224&rfr_iscdi=true